AMGEN INC

THOUSAND OAKS, CA How do I update this listing?

Amgen is based out of Thousand Oaks. Amgen Inc. (Amgen) is an independent biotechnology medicines company. The Company discovers, develops, manufactures and markets medicines for grievous illnesses. It focuses on human therapeutics and concentrates on medicines based on advances in cellular and molecular biology. Its principal products include Aranesp (darbepoetin alfa) and EPOGEN (Epoetin alfa), erythropoietic-stimulating agents (ESAs) that stimulate the production of red blood cells; Neulasta (pegfilgrastim), a pegylated protein, based on the Filgrastim molecule, and NEUPOGEN (Filgrastim), a recombinant-methionyl human granulocyte colony-stimulating factor (G-CSF), both of which selectively stimulate the production of neutrophils (a type of white blood cell that helps the body fight infection), and Enbrel (etanercept), an inhibitor of tumor necrosis factor (TNF), a substance that plays a role in the body's response to inflammatory diseases.Whalewisdom has at least 7 13D filings, 16 13G filings, and 512 Form 4 filings The firm last filed a Form D notice of exempt offering of securities on 2015-01-23. The notice included securities offered of Other

Create Email Alert

Contact Info

amgen inc
ONE AMGEN CENTER DRIVE
THOUSAND OAKS CA    91320

Business Phone: (805)447-1000
SEC SIC CODE:
2836-BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Current 13D/G Holdings
Stock Sector Shares Held Market Value Rank Source Source Date
BeiGene Ltd ADR (BGNE) HEALTH CARE 206,635,013 34,284,881,356.96 1 13D 2020-01-02
Akero Therapeutics Inc (AKRO) HEALTH CARE 1,905,708 42,297,189.06 2 13G 2019-12-31
Provention Bio Inc (PRVB) HEALTH CARE 2,500,010 17,062,568.25 3 13G 2019-09-23
Kezar Life Sciences Inc (KZR) HEALTH CARE 504,438 2,022,796.38 4 13G 2019-12-31

Active Schedule 13D and 13G events

Sign in to see

Form 4 - Recent Insider Transactions

Loading...

Form D Filings

Form D is a form to be used to file a notice of an exempt offering of securities with the Securities and Exchange Commission. Form D contains basic information about the offering and the company.

Form D Filings
Filing Date Form Type Industry Group Securities Offered Total Offering Amount Total Amount Sold Total Remaining
2015-01-23 D/A BIOTECHNOLOGY Other 2,500,000,000 0 2,500,000,000
2014-01-29 D/A BIOTECHNOLOGY Other 2,500,000,000 0 2,500,000,000
2013-02-04 D/A BIOTECHNOLOGY Other 2,500,000,000 0 2,500,000,000
2012-02-29 D/A BIOTECHNOLOGY Other 2,500,000,000 0 2,500,000,000
2011-03-14 D BIOTECHNOLOGY Other 2,322,500,000 0 2,322,500,000
Other Issuers in Filings
Name Address
No Other Issuers
Related Parties included in filings
Name Address Relationship
ANNA S RICHO subscription required
    EXECUTIVE OFFICER
ANTHONY C. HOOPER subscription required
    EXECUTIVE OFFICER
BRIAN M MCNAMEE subscription required
    EXECUTIVE OFFICER
CYNTHIA PATTON subscription required
    EXECUTIVE OFFICER
DAVID BALTIMORE subscription required
    DIRECTOR
DAVID W BEIER subscription required
    EXECUTIVE OFFICER
DAVID W. MELINE subscription required
    EXECUTIVE OFFICER
DAVID PIACQUAD subscription required
    EXECUTIVE OFFICER
DAVID J SCOTT subscription required
    EXECUTIVE OFFICER
FABRIZIO BONANNI subscription required
    EXECUTIVE OFFICER
FRANCOIS DE CARBONNEL subscription required
    DIRECTOR
FRANK J BIONDI, JR. subscription required
    DIRECTOR
FRANK C HERRINGER subscription required
    DIRECTOR
FREDERICK W GLUCK subscription required
    DIRECTOR
GILBERT S OMENN subscription required
    DIRECTOR
GREG C. GARLAND subscription required
    DIRECTOR
J PAUL REASON subscription required
    DIRECTOR
J. PAUL REASON subscription required
    DIRECTOR
JERRY D CHOATE subscription required
    DIRECTOR
JONATHAN M PEACOCK subscription required
    EXECUTIVE OFFICER
JUDITH C PELHAM subscription required
    DIRECTOR
KEVIN W SHARER subscription required
    EXECUTIVE OFFICER DIRECTOR
LEONARD D SCHAEFFER subscription required
    DIRECTOR
MADHAVAN BALACHANDRAN subscription required
    EXECUTIVE OFFICER
MICHAEL A. KELLY subscription required
    EXECUTIVE OFFICER
R. SANDERS WILLIAMS subscription required
    DIRECTOR
REBECCA HENDERSON subscription required
    DIRECTOR
ROBERT A BRADWAY subscription required
    EXECUTIVE OFFICER
ROBERT A. ECKERT subscription required
    DIRECTOR
ROGER M PERLMUTTER subscription required
    EXECUTIVE OFFICER
RONALD D SUGAR subscription required
    DIRECTOR
SCOTT A. TROSS subscription required
    EXECUTIVE OFFICER
SEAN E. HARPER subscription required
    EXECUTIVE OFFICER
STUART A. TROSS subscription required
    EXECUTIVE OFFICER
THOMAS DITTRICH subscription required
    EXECUTIVE OFFICER
TYLER JACKS subscription required
    DIRECTOR
VANCE D COFFMAN subscription required
    DIRECTOR

**EXPERIMENTAL** Current Hong Kong Exchange Long Positions

Updated daily

Holder Issuer Transaction Date Transaction Type Avg PPS Shares Involved Shares Owned % Capital Origin
Amgen Inc. BeiGene, Ltd. 2020-01-02 Long 0.0 206,635,013 206,635,013 20.5% Hong Kong

Position History

Holder Issuer Transaction Date Transaction Type Avg PPS Shares Involved Shares Owned % Capital Origin
Amgen Inc. BeiGene, Ltd. 2019-10-31 Long 0.0 203,282,820 203,282,820 20.5% Hong Kong

Elevate your investments